Tonix製藥控股 TNXP 深 滬
交易中 08-13 11:06:50 美东时间
12.375
+0.405
+3.38%
華盛通- 最 高12.50
- 今 開12.00
- 成交量 18.77万股
- 最 低 11.79
- 昨 收 11.97
- 總市值 1.97亿
- 52周最高 37.56
- 市盈率 靜 --
- 換手率 1.18%
- 52周最低 9.40
- 委 比 4.76%
- 總股本 1594.08万
- 歷史最高 13440000000.00
- 量 比 1.47
- 振 幅 5.93%
- 歷史最低 9.40
- 每 手 1
- 風險率 7.86%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多财报速睇 | Tonix制药控股 2026财年Q2营收0.14亿美元，同比增长577.9%；归母净利润亏损0.41亿美元，同比亏损扩大43.4%
华盛资讯8月10日讯，Tonix制药控股公布2026财年Q2业绩，公司Q2营收0.14亿美元，同比增长577.9%，归母净利润亏损0.41亿美元，同比亏损扩大43.4%。
08-10 20:36
Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences
Tonix Pharmaceuticals Holding Corp. announced that its management team will participate in two investor conferences in August and September 2026. Seth Lederman, M.D., President and CEO, will present at the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11 and attend 1x1 meetings at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on September 16. Tonix is a biotech company focused on CNS disorders, infe...
08-05 11:00
Tonix Pharma Receives Official Minutes From Type C Meeting With FDA To Discuss Plans For Adaptive Phase 2 Field Study Of TNX-4800 To Prevent Lyme Disease In Adults In US
Alignment with FDA on key elements of the study design support planned start of the Phase 2 study in the first quarter of 2027 Long-acting monoclonal antibody TNX-4800 is a rapidly acting alternative to vaccination against Lyme disease with potential advantages in efficacy and tolerability over vacc...
08-03 19:11
Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026
Tonix Pharmaceuticals Holding Corp. will host a conference call and webcast on August 10, 2026, at 8:30 a.m. ET to discuss its second quarter 2026 financial results and operational highlights. Registration links for the call and webcast are provided, with a replay available on the company’s website. Tonix, a commercial-stage biotech company, focuses on CNS disorders, infectious diseases, immunology, and rare diseases. Its flagship product, TONMYA...
07-27 11:00
Tonix Pharma Announces Publication Of Monkeypox Study In Journal Of Virology, Peer-Reviewed Publication Of ASM
Data show clade IIb from 2022 outbreak is 100 to 100,000-fold less virulent than clade IIa from 2003 outbreak Three new models for investigating mpox infection and pathogenesis identified Tonix is advancing TNX-801, a live, attenuated, minimally replicative investigational vaccine candidate based on...
07-15 21:07
Tonix Pharma expands Medicare coverage for TONMYA therapy
The latest announcement is out from Tonix Pharma ( ($TNXP) ). On July 13, 2026,...
07-13 19:54
Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA®
Tonix Pharmaceuticals announced a major Medicare agreement for TONMYA, adding approximately 9 million Medicare lives (16% of 55 million Medicare beneficiaries in the U.S.) effective January 1, 2027. Combined with prior commercial payer agreements and Medicaid coverage, TONMYA will cover about 46% of all U.S. covered lives (145 million out of 314 million). The company is expanding its sales force, adding 50 new representatives by mid-third quarter...
07-13 11:00
美股大行评级 | 潜在涨幅135.66%！Ocular Therapeutix获Chardan Capital升目标价至23美元，维持"买入"评级
今日重点评级关注：Chardan Capital：维持Ocular Therapeutix"买入"评级，目标价从21美元升至23美元；Guggenheim：维持Amylyx Pharmaceuticals"买入"评级，目标价从30美元升至40美元
06-26 17:42
